-
Inmagene’s Tavalisse First Prescribed in China for ITP Treatment
•
China-based Inmagene Biopharmaceuticals has announced that its in-licensed drug Tavalisse (fostamatinib) has been first prescribed at the Hainan branch of Shanghai’s Ruijin Hospital. This marks a significant milestone in the availability of the oral spleen tyrosine kinase (SYK) inhibitor for the treatment of immunization thrombocytopenia (ITP) in China. Background and…
-
China’s Party and State Institutions Reshuffle: Key Changes for Healthcare and Finance
•
The second plenary session of the 20th Communist Party of China (CPC) Central Committee has passed a significant plan to reshuffle party and national institutions. Several changes will impact the healthcare industry and other key sectors, reflecting a strategic reorganization aimed at enhancing governance and efficiency. Healthcare Sector Changes Financial…
-
BrightGene’s Generic Halaven Approved for Marketing in China
•
China-based BrightGene Bio-Medical Technology Co., Ltd (SHA: 688166) has received marketing approval from the National Medical Products Administration (NMPA) for its generic version of Japan-based Eisai’s (TYO: 4523) cancer therapy Halaven (eribulin). The approval signifies that BrightGene’s product, trade-named BoLiNing, has passed the generic quality consistency evaluation (GQCE). BoLiNing is…
-
Abcam and MEDx Expand Strategic Partnership on Claudin 18.2 Diagnosis
•
UK-based abcam (NASDAQ:ABCM) has announced a licensing agreement with China-headquartered MEDx Translational Medicine Co., Ltd, further expanding their strategic partnership initiated in 2021. The collaboration will focus on development, regulatory filings, and commercialization related to Claudin 18.2 concomitant diagnosis. Financial details of the agreement were not disclosed. About AbcamAbcam is…
-
Inovio and ApolloBio Announce Positive Phase III Data for VGX-3100 Vaccine
•
US-based Inovio Pharmaceuticals (NASDAQ: INO) and China-based ApolloBio Corp. (NEEQ:430187) have announced positive data from the Phase III Reveal 2 study for the DNA therapeutic vaccine VGX-3100 (known as ABC-3100 in China). The two firms are co-developing VGX-3100 under a 2018 licensing deal, with ApolloBio holding development and commercialization rights…
-
Sunshine Medical Procurement Platform Announces VBP Tender Results for Yangtze River Delta
•
Shanghai’s Sunshine Medical Procurement All-In-One (SMPA) platform has revealed the resultant winning bids and spare supply manufacturers for the Yangtze River Delta Alliance volume-based procurement (VBP) tender. The tender involves Shanghai, Zhejiang, and Anhui, and the platform has also disclosed the prices of the winning bids and spare products. Tender…
-
Neo Modulus Secures Series B Funding for Regenerative Medical Device Development
•
Neo Modulus, a developer of regenerative implantable medical devices based in Suzhou, has reportedly raised “hundreds of millions” of renminbi in a Series B financing round. The round was led by SND Financial Holdings, with participation from JM Capital, CDH Investments, Hui Ding Capital, 10Fund, and Boya Clivia Venture Capital.…
